Pacira Pharmaceuticals Inc (PCRX) was Initiated by Goldman to “Neutral”. Goldman advised their investors in a research report released on Dec 1, 2016.
Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Shares were Reiterated by Mizuho on Nov 3, 2016 to “Buy” and Lowered the Price Target to $ 46 from a previous price target of $64 .Shares were Reiterated by Wedbush on Oct 19, 2016 to “Outperform” and Lowered the Price Target to $ 93 from a previous price target of $109 .Pacira Pharmaceuticals Inc was Resumed by Brean Capital to “Hold” on Oct 7, 2016.
On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.25 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $-0.05. The company had revenue of $68.40 million for the quarter, compared to analysts expectations of $67.16 million. The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS.
Pacira Pharmaceuticals Inc opened for trading at $31.5 and hit $32.45 on the upside on Tuesday, eventually ending the session at $32.15, with a gain of 2.39% or 0.75 points. The heightened volatility saw the trading volume jump to 8,12,975 shares. Company has a market cap of $1,202 M.
In a different news, on Nov 17, 2016, David M Stack (CEO and Chairman) sold 15,000 shares at $37.49 per share price. According to the SEC, on Nov 17, 2016, James S Scibetta (President) sold 20,000 shares at $36.50 per share price. On Jun 8, 2016, Lauren Bullaro Riker (Vice President, Finance) sold 938 shares at $47.67 per share price, according to the Form-4 filing with the securities and exchange commission.
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.